Irofulven (MGi Pharma)
Baekelandt, M.
Current Opinion in Investigational Drugs 3(10): 1517-1526
2002
ISSN/ISBN: 1472-4472 PMID: 12431030 Document Number: 7031
MGI Pharma is developing irofulven, a semi-synthetic compound derived from illudin S, a toxin from the Omphalotus illudens mushroom, for the potential treatment of refractory and relapsed tumors, including ovarian, prostate, hepatocellular, breast, lung and colon cancers. Phase II trials of the compound as a monotherapy or in combination therapies are ongoing for a number of these indications.
Document emailed within 1 workday
